| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 06/18/2013 | US8465737 Three-dimensional structure of complement receptor type 2 and uses thereof |
| 06/18/2013 | CA2635692C Human anti-il-23 antibodies, compositions, methods and uses |
| 06/18/2013 | CA2554635C Compounds, compositions containing such compounds and methods of treatment of autoimmune diseases using such compounds |
| 06/18/2013 | CA2459348C Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| 06/18/2013 | CA2446087C Recombinant tumor specific antibody and use thereof |
| 06/18/2013 | CA2440028C Rearranged squamous cell carcinoma antigen genes ii |
| 06/18/2013 | CA2418144C Urocortin proteins and uses thereof |
| 06/18/2013 | CA2278523C Rna binding protein and binding site useful for expression of recombinant molecules |
| 06/13/2013 | WO2013086533A1 Neutralizing antibodies to hiv-1 and their use |
| 06/13/2013 | WO2013086448A2 IgG2 DISULFIDE ISOFORM SEPARATION |
| 06/13/2013 | WO2013086443A1 Agonistic human lcat antigen binding proteins and their use in therapy |
| 06/13/2013 | WO2013085972A1 Pdgf receptor beta binding polypeptides |
| 06/13/2013 | WO2013085893A1 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| 06/13/2013 | WO2013085550A2 V1v2 immunogens |
| 06/13/2013 | WO2013084504A1 Method for predicting hypertension |
| 06/13/2013 | WO2013084371A1 Recombinant protein capable of binding specifically and rapidly to human cardiac troponin i |
| 06/13/2013 | WO2013083906A1 Use of at least one biomarker for the in vitro prognosis or diagnosis of lymphoproliferative episodes associated with the epstein-barr virus (ebv) |
| 06/13/2013 | WO2013083720A1 Antibodies anti-spla2-x and uses thereof |
| 06/13/2013 | WO2013083659A1 Combination treatment comprising ho - 1 inhibitor and immunotherapeutic agent |
| 06/13/2013 | WO2013083497A1 Antibody formulation |
| 06/13/2013 | WO2013059524A3 Antibodies directed against influenza |
| 06/13/2013 | WO2013057281A3 Modulation of macrophage activation |
| 06/13/2013 | WO2013056851A3 Stable multiple antigen-binding antibody |
| 06/13/2013 | WO2013045707A3 Biological materials related to c-met |
| 06/13/2013 | WO2013033008A9 Tandem fc bispecific antibodies |
| 06/13/2013 | WO2013026004A3 Antibodies that bind integrin alpha-v beta-8 |
| 06/13/2013 | WO2013016648A3 Stabilized formulations containing anti-pcsk9 antibodies |
| 06/13/2013 | WO2012175643A3 Binding domains directed against gpcr:g protein complexes and uses derived thereof |
| 06/13/2013 | WO2012155134A3 Assay reagents for a neurogranin diagnostic kit |
| 06/13/2013 | WO2012032181A9 Antibody derivatives |
| 06/13/2013 | WO2011002721A8 Non-human mammal model of human hematopoietic cancer |
| 06/13/2013 | US20130150563 Lipid-conjugated antibodies |
| 06/13/2013 | US20130150561 Single-domain brain-targeting antibody fragments derived from llama antibodies |
| 06/13/2013 | US20130150560 AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-SURROGATES, ADDL-BINDING MOLECULES, AND USES THEREOF |
| 06/13/2013 | US20130150559 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| 06/13/2013 | US20130150558 Design and development of masked therapeutic antibodies to limit off-target effects; application to anti-egfr antibodies |
| 06/13/2013 | US20130149793 Anti-fdp monoclonal antibody, fdp measurement reagent and reagent kit using same, and fdp measurement method |
| 06/13/2013 | US20130149772 Magnetic ion-exchange resin and method for the preparation thereof |
| 06/13/2013 | US20130149711 BARD1 Isoforms in Lung and Colorectal Cancer and Use Thereof |
| 06/13/2013 | US20130149316 Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof |
| 06/13/2013 | US20130149315 Antibodies against glucagon receptor and their use |
| 06/13/2013 | US20130149313 Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
| 06/13/2013 | US20130149309 Novel regulatory proteins and inhibitors |
| 06/13/2013 | US20130149308 Antibodies to il-1beta and il-18, for treatment of disease |
| 06/13/2013 | US20130149307 Humanized anti-egfl7 antibodies and methods using same |
| 06/13/2013 | US20130149305 Soluble cd80 as a therapeutic to reverse immune supression in cancer patients |
| 06/13/2013 | US20130149301 Anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
| 06/13/2013 | US20130149300 MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS |
| 06/13/2013 | US20130149299 Dosages for treatment with anti-egfr antibodies |
| 06/13/2013 | US20130149298 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| 06/13/2013 | US20130149297 Role of fragile x mental retardation gene and protein in cancer metastasis |
| 06/13/2013 | US20130149246 Human Monoclonal Antibodies Against Hendra and Nipah Viruses |
| 06/13/2013 | US20130149236 Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof |
| 06/13/2013 | CA2858716A1 Neutralizing antibodies to hiv-1 and their use |
| 06/13/2013 | CA2858572A1 Agonistic human lcat antigen binding proteins and their use in therapy |
| 06/13/2013 | CA2858463A1 Antibodies anti-spla2-x and uses thereof |
| 06/13/2013 | CA2858347A1 V1v2 immunogens |
| 06/13/2013 | CA2858012A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 06/13/2013 | CA2857939A1 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
| 06/13/2013 | CA2857721A1 Pdgf receptor beta binding polypeptides |
| 06/13/2013 | CA2857601A1 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| 06/13/2013 | CA2857194A1 Igg2 disulfide isoform separation |
| 06/13/2013 | CA2853138A1 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| 06/12/2013 | EP2602265A1 Antibodies anti-sPLA2-X and uses thereof |
| 06/12/2013 | EP2601967A1 Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids |
| 06/12/2013 | EP2601966A1 Treatment of neurological or neurodegenerative disorders |
| 06/12/2013 | EP2601934A1 Vesicular phospholipid gels comprising proteinaceous substances |
| 06/12/2013 | EP2601298A1 Mice that make binding proteins comprising vl domains |
| 06/12/2013 | EP2601220A2 Use of her3 binding agents in prostate treatment |
| 06/12/2013 | EP2601219A2 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| 06/12/2013 | EP2601218A2 Dual variable domain immunoglobulins and uses thereof |
| 06/12/2013 | EP2601217A2 Antibodies directed against il-17 |
| 06/12/2013 | EP2601216A1 Covalent diabodies and uses thereof |
| 06/12/2013 | EP2601215A1 Process for the production of anti-idiotype monoclonal antibodies for diagnostic and/or therapeutic use |
| 06/12/2013 | EP2601212A1 Methods and compounds for the diagnosis and treatment of |
| 06/12/2013 | EP2600898A1 Anti-mhc antibody anti-viral cytokine fusion protein |
| 06/12/2013 | EP2600896A2 Treating breast cancer with anti-il-19 antibody |
| 06/12/2013 | EP2600895A1 Chronic lymphocytic leukemia (cll) biomarkers |
| 06/12/2013 | EP2600889A2 Anti-la antibodies and their use for immunotargeting |
| 06/12/2013 | EP2600882A1 Antibodies against 6-sulfo-lacnac-positive human dendritic cells, and their use |
| 06/12/2013 | EP2600878A2 Regulatory b cells and their uses |
| 06/12/2013 | EP2600843A2 Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
| 06/12/2013 | CN1942588B Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/12/2013 | CN1842538B Modified binding molecules comprising connecting peptides |
| 06/12/2013 | CN1529753B Disease-associated protein |
| 06/12/2013 | CN1461310B ANtibodies that bind human interleukin-18 and methods of making and using |
| 06/12/2013 | CN103154255A Mice that make binding proteins comprising VL domains |
| 06/12/2013 | CN103154038A Anti-fap antibodies and methods of use |
| 06/12/2013 | CN103154037A Anti-IL 12 Rbeta 1 antibodies and their use in treating autoimmune and inflammatory disorders |
| 06/12/2013 | CN103154036A Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin FC compositions |
| 06/12/2013 | CN103154035A Monoclonal antibodies against her2 |
| 06/12/2013 | CN103154034A Antibodies that bind human cd27 and uses thereof |
| 06/12/2013 | CN103154033A Stable and soluble antibodies |
| 06/12/2013 | CN103154032A Antibodies to IL-1beta and IL-18, for treatment of disease |
| 06/12/2013 | CN103154031A Methods of treating psoriasis using il-17 antagonists |
| 06/12/2013 | CN103154030A Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| 06/12/2013 | CN103154029A Antibodies against human TWEAK and uses thereof |
| 06/12/2013 | CN103154028A Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
| 06/12/2013 | CN103154027A Soluble human st-2 antibodies and assays |
| 06/12/2013 | CN103154026A Antibodies directed against il-17 |